VIVUS (VVUS) CEO Wilson Issues Shareholder Letter; Plans on Broader Qsiva Expansion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
UPDATE: Lazard Capital Downgrades Vivus (VVUS) to Neutral
May 14, 2013 6:51 AM EDT(Updated - May 14, 2013 7:35 AM EDT)
Lazard Capital downgraded Vivus (NASDAQ: VVUS) from Buy to Neutral. Analyst Joshua Schimmer said time is running out for Vivus and its obesity treatment Qsymia, as demand fails to materialize.
He thinks the company needs to see... More
VIVUS (VVUS) Appoints Two New Directors
May 13, 2013 7:01 AM EDTVIVUS, Inc. (Nasdaq: VVUS) announced the appointment of J. Martin Carroll and Jorge Plutzky, M.D. to its Board of Directors.
Mr. Carroll has more than 35 years of executive level experience in the pharmaceutical industry. He served most recently in key roles at... More
